Synthetic cannabinoid (K2) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Synthetic cannabinoid (K2) antibodies (anti-Synthetic cannabinoid, anti-K2) and diagnostic hapten-carrier conjugates BSA-Synthetic cannabinoid (K2), OVA-Synthetic cannabinoid (K2), KLH-Synthetic cannabinoid (K2) antigens for Multiple disease K2 detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Multiple disease diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-233-Ag01BSA-Synthetic cannabinoid (K2)$756.00
GMP-SMT-233-Ag02OVA-Synthetic cannabinoid (K2)$756.00
GMP-SMT-233-Ab01Anti-human Synthetic cannabinoid (K2) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-233-Ab02Anti-human Synthetic cannabinoid (K2) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Synthetic cannabinoid (K2)

Cat No.GMP-SMT-233-Ag01
Product NameBSA-Synthetic cannabinoid (K2)
TargetSynthetic cannabinoid (K2)
Expression platformSynthetic
Bioactivity validationSynthetic cannabinoid (K2) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in K2 level test of Multiple disease and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Synthetic cannabinoid (K2) / OVA-Synthetic cannabinoid (K2) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Synthetic cannabinoid (K2)

Cat No.GMP-SMT-233-Ag02
Product NameOVA-Synthetic cannabinoid (K2)
TargetSynthetic cannabinoid (K2)
Expression platformSynthetic
Bioactivity validationSynthetic cannabinoid (K2) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in K2 level test of Multiple disease and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Synthetic cannabinoid (K2) / OVA-Synthetic cannabinoid (K2) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Synthetic cannabinoid (K2) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-233-Ab01
Product NameAnti-human Synthetic cannabinoid (K2) mouse monoclonal antibody (mAb)
TargetSynthetic cannabinoid (K2)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationSynthetic cannabinoid (K2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Synthetic cannabinoid (K2) antibodies in K2 level test of Multiple disease and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Synthetic cannabinoid (K2) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Synthetic cannabinoid (K2) human monoclonal antibody (mAb)

Cat No.GMP-SMT-233-Ab02
Product NameAnti-human Synthetic cannabinoid (K2) human monoclonal antibody (mAb)
TargetSynthetic cannabinoid (K2)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationSynthetic cannabinoid (K2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Synthetic cannabinoid (K2) antibodies in K2 level test of Multiple disease and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Synthetic cannabinoid (K2) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. Illuminating the World of Synthetic Cannabinoids in In Vitro Diagnosis (IVD)

    Synthetic cannabinoids, also commonly known as synthetic marijuana or designer drugs, constitute a category of artificially engineered chemical compounds designed to replicate the effects of naturally occurring cannabinoids found in the cannabis plant. These synthetic substances, often sprayed onto plant material for inhalation or vaporization, have garnered notoriety for their capricious and potentially hazardous impacts on human health. Their usage has given rise to significant public health concerns, prompting the imperative for advanced diagnostic methodologies that can accurately ascertain their presence.

    Within the domain of in vitro diagnosis (IVD), synthetic cannabinoids assume a pivotal role as target molecules for diagnostic assays. Our esteemed biopharmaceutical enterprise specializes in providing an array of resources designed to facilitate the development of advanced diagnostic tests that target these synthetic compounds. These resources encompass anti-synthetic cannabinoid antibodies and a comprehensive suite of small molecule competitive antigens. Each of these components is meticulously crafted to cater to the specific needs of diagnostic test development, enabling precise and sensitive quantification of synthetic cannabinoids across a spectrum of biological samples. This elevation of diagnostic precision is instrumental in not only detecting the presence of synthetic cannabinoids but also differentiating between various chemical analogs and formulations.

    2. The Imperative of Measuring Synthetic Cannabinoids

    The measurement of synthetic cannabinoids assumes paramount significance for several compelling reasons:

    a. Public Health and Safety: Synthetic cannabinoids have been linked to a myriad of adverse effects, ranging from seizures and hallucinations to cardiovascular complications and, in severe cases, fatalities. The accurate measurement of these compounds is pivotal in monitoring their prevalence and identifying potential outbreaks or hazardous formulations, thereby safeguarding public health and safety.

    b. Clinical Evaluation: In specific clinical scenarios, healthcare professionals may find it imperative to assess the presence of synthetic cannabinoids in patients, especially when presented with symptoms or medical histories that suggest exposure. Precise measurement facilitates clinical decision-making and enhances patient management, allowing for tailored therapeutic interventions.

    c. Forensic Investigations: In legal and forensic contexts, the measurement of synthetic cannabinoids holds paramount importance. It serves as a crucial component in confirming their presence in bodily fluids or tissues, thereby supporting legal proceedings and investigations related to drug-related offenses.

    d. Research and Legislation: The data generated through comprehensive measurement efforts are of immense value to researchers and policymakers alike. Such data aids in understanding trends associated with synthetic cannabinoid usage, devising effective intervention strategies, and formulating legislation that addresses the complexities surrounding these synthetic compounds.

    e. Drug Testing and Rehabilitation: The accurate measurement of synthetic cannabinoids is indispensable in supporting drug testing initiatives across various settings, such as workplace drug testing or addiction rehabilitation facilities. It plays a pivotal role in monitoring substance use for compliance and facilitating the process of recovery.

    In summation, the meticulous measurement of synthetic cannabinoids through advanced diagnostic assays within the domain of in vitro diagnosis (IVD) serves as a linchpin for the preservation of public health, the enhancement of clinical assessments, the facilitation of forensic investigations, the advancement of scientific research, and the promotion of compliance across diverse contexts. Our specialized suite of products, custom-tailored specifically for synthetic cannabinoid analysis, stands as an indispensable resource in meeting these multifaceted requirements. These resources ensure the precise detection of synthetic cannabinoids, contributing significantly to the well-being of individuals and communities alike.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.